他の暗号通貨に移動
Avidity Biosciences, Inc.
RNAM重要なポイント
最終更新日時:: 2026-04-13- •Replimune (REPLI) closed at $4.76 on April 10, 2026 — a ~20% single-day drop and 51% YTD decline following a second FDA Complete Response Letter for RP1.
- •Leverage risk is extreme: a 50x long CFD opened at $5.91 would have been liquidated intraday, as the 20% decline represents ~10x the initial margin at that leverage level.
- •A February 2026 SEC filing warned a second rejection could make RP1 development 'no longer viable,' with Phase 3 completion not expected until January 2029.
- •Cross-market contagion targets biotech ETFs (XBI, IBB) as the FDA rejection reinforces sector-wide regulatory uncertainty flagged by nearly half of RBC Capital Markets-surveyed investors.
- •FDA leadership transition (Vinay Prasad departing by end of April 2026) adds short-term regulatory uncertainty across clinical-stage oncology names.
価格と市場構造
取引レジームのステータス
用語集
Key listed-stock and CFD terms, one line each — so the page is unambiguous for both readers and AI answer engines.
| Stock CFD | A contract for difference on a share price — price exposure only, not ownership of the underlying shares. |
|---|---|
| Extended hours | Pre-market and after-hours trading outside the exchange’s regular session. |
| Basis risk | The risk that the CFD reference price and the exchange execution price do not move in step. |
| P/E | Price-to-earnings ratio = share price ÷ earnings per share; a common valuation gauge. |
| Gross margin | Gross profit ÷ revenue; reflects product-level profitability. |
| EPS | Earnings per share = net income ÷ diluted shares outstanding. |
最新のパルス
Replimune、2回目のFDA拒否でYTD56%急落:レバレッジリスクとバイオテックセクターへの波及
FierceBiotechおよびBioPharma Diveによると、米国食品医薬品局(FDA)は2026年4月10日にReplimune Group(NASDAQ: REPLI)の切除不能な進行皮膚メラノーマ向けのRP1(ヴソリモゲン・オダーペルベック)に対して2回目の完全回答書(CRL)を発行しました。FDAの治療製品局は、フェーズ1/2 Ignyte試験のデータは「有効性の substant
Replimuneの2回目のFDA拒否:レイオフがバイオテクノロジーCFDトレーダーにとってのバイナリーリスク崩壊を示唆
2026年4月10日、米国食品医薬品局(FDA)は、Replimune Group, Inc.(NASDAQ: REPL)の再提出された生物製剤承認申請(BLA)に対して2回目の完全回答書(CRL)を発行し、RP1(ヴソリモゲン・オルダペルベック)の拒否を発表しました。これは、ブリストル・マイヤーズ スクイブのオプジボと併用して高度な黒色腫を対象とした腫瘍溶解性免疫療法です。FierceBiote
Replimune's RP1 Faces Second FDA Verdict: What April 10 Means for Biotech CFD Traders
Replimune Group Inc. (NASDAQ: REPL) received a Complete Response Letter (CRL) from the FDA on July 22, 2025, rejecting its Biologics License Application for RP1 — an oncolytic herpes simplex virus — i
Get Started with Avidity Biosciences, Inc.
Start trading Avidity Biosciences, Inc. on CoinUnited.io with industry-leading leverage and zero fees.
Trade with Leverage
Trade RNAM CFDs with up to 1000x leverage on CoinUnited.io.
- Up to 1000x leverage
- Zero trading fees
- Advanced risk management tools
Explore Stocks
Browse the full stocks market on CoinUnited.io with 125+ instruments.
- 125+ stocks instruments
- Real-time market data
- Professional charting tools
Learn Stocks Trading
Read our in-depth research and analysis on stocks markets.
- Expert market analysis
- Technical analysis basics
- Daily market insights
How to Trade Avidity Biosciences, Inc.: Step-by-Step Guide
Learn how to trade Avidity Biosciences, Inc. (RNAM) on CoinUnited.io with up to 1000x leverageand zero trading fees. Follow this simple step-by-step guide to start CFD trading today.
Create Your CoinUnited.io Account
Sign up at CoinUnited.io in under a minute. You'll need an email address to get started.
- ✓Quick and free registration
- ✓Email and password setup
- ✓Two-factor authentication for security
Verify Your Identity
Complete the KYC verification process to unlock full trading features and higher limits.
- ✓Upload government-issued ID
- ✓Proof of address document
- ✓Usually verified within minutes
Deposit Funds
Fund your account using one of the supported deposit methods.
Deposit Methods
- •Cryptocurrency deposits (BTC, ETH, USDT)
- •Bank transfer available
- •No minimum deposit requirement
Find RNAM in the Stocks Section
Navigate to the stocks market section and search for RNAM. You can trade Avidity Biosciences, Inc. as a CFD with up to 1000x leverage.
- ✓Search for "RNAM" in the trading platform
- ✓Select CFD trading mode
- ✓Review the current price and market data
Place Your Trade
Choose your position direction (long or short), set your leverage, and enter your position size to trade Avidity Biosciences, Inc..
- ✓Long (buy) if you expect RNAM to rise
- ✓Short (sell) if you expect RNAM to fall
- ✓Set stop-loss and take-profit levels
Monitor & Manage Risk
Keep track of your open positions and manage risk with stop-loss orders and position sizing.
- ✓Monitor P&L in real-time
- ✓Adjust stop-loss as needed
- ✓Never risk more than you can afford to lose
Order Types
Market Order
Execute immediately at the current market price. Best for quick entries.
Limit Order
Set a specific price to enter. The order fills only when the market reaches your price.
Stop-Loss Order
Automatically close your position at a specified price to limit potential losses.
Important Tips
- • Start with a small position to understand how leverage works
- • Always set a stop-loss to protect your capital
- • Higher leverage amplifies both gains and losses
- • Never invest more than you can afford to lose
タグ
Similar Stocks Assets
Explore other stocks instruments in the same sector as Avidity Biosciences, Inc.. Compare performance and find trading opportunities.
ProShares UltraShort Silver

AeroVironment, Inc.

Tempus AI, Inc

Ondas Holdings Inc.

TransUnion
免責事項および参考文献
重要なリスク免責事項
A CoinUnited stock CFD gives price exposure to Avidity Biosciences, Inc. only, not equity ownership: no shareholder voting rights, no dividends, and no settlement in the underlying share.
Leverage magnifies losses as well as gains, and a position can be liquidated long before the underlying share price recovers. The underlying listing trades on exchange hours, so the reference price can gap between sessions.
投資判断を行う前には、利用者ご自身で十分な調査を行い、信頼できる金融専門家に相談することを推奨します。本プラットフォームの作成者および運営者は、提供された情報に依拠したことにより発生した金融損失やその他の損害について、一切の責任を負いかねます。
Leveraged trading is extremely risky and you may lose your entire deposit.
方法論の概要
Figures on this page are compiled from primary and named third-party sources, not produced by a forecasting model. Each one carries its source and date in the Source Map above.
- Financial statements: the company’s own SEC filings (10-K / 10-Q), read from XBRL
- Market data: the CoinUnited reference price and daily closes
- Institutional ownership: SEC Form 13F quarterly filings
- Analyst targets: aggregated third-party sell-side coverage — third-party opinion, not CoinUnited’s view
- Peer multiples: third-party trailing-twelve-month ratios
CoinUnited does not publish a price forecast or target for Avidity Biosciences, Inc..
最新の方法論の見直し:
Avidity Biosciences, Inc.の取引を始める準備はできましたか?
何千人ものトレーダーに参加し、今日からAvidity Biosciences, Inc.の取引を始めましょう。高度な取引ツールと競争力のある手数料にアクセスできます。



